Concert Pharmaceuticals, a pharmaceutical company based in the United States, has announced the discovery of a miracle drug that can cure baldness or alopecia. Photo: Collected

“>


A cure for alopecia or baldness has been discovered by scientists from Concert Pharmaceuticals, a pharmaceutical company based in the United States.

Concert Pharmaceuticals, a pharmaceutical company based in the United States, has announced the discovery of a miracle drug that can cure baldness or alopecia. Photo: Collected

Alopecia or baldness is considered an incurable disease. However, researchers from Concert Pharmaceuticals, a pharmaceutical company based in the United States, have announced the discovery of an elixir to achieve the impossible.

The pharmaceutical company announced the sighting, during their phase three trials of the miracle drug. In a statement to the New York Post, he said the twice-daily pill, also known as CTP-543, would be a “milestone” in the treatment of hair loss and baldness, for which there is currently no cure.

For all the latest news, follow the Daily Star’s Google News channel.

Their statement also informed that in their latest trial, 706 patients with baldness were selected for 24 weeks. These people, residing in the United States, Canada and Europe, were between 18 and 65 years old. On average, patients had only 16% hair at the start of the trial, with 0% having more than 50% hair.

Bald patients were divided into three groups. One group received two doses of 8 mg per day, the second group received two doses of 12 mg tablets and the third group received a placebo. Compared to those who received a placebo, those who received medication witness “significant growth” of hair.

Side effects such as headaches and acne were observed in some of the patients who took part in the test. However, the pharmaceutical group informed that the drug was well tolerated and only 5% of patients complained of headaches, acne and infections.

After repeating the phase three trial in 517 people again, the company hopes to seek approval from the Food and Drug Administration (FDA), the US drug regulator, next year.